ORAL CAVITY SQUAMOUS CELL CARCINOMA
Clinical trials for ORAL CAVITY SQUAMOUS CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new ORAL CAVITY SQUAMOUS CELL CARCINOMA trials appear
Sign up with your email to follow new studies for ORAL CAVITY SQUAMOUS CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New Two-Pronged attack on mouth cancer shows promise
Disease control Recruiting nowThis study is testing whether adding two immunotherapy drugs (tiragolumab and atezolizumab) before and after standard surgery and chemoradiation can better control advanced oral cavity cancer. It is for adults newly diagnosed with a specific type of tumor (PD-L1 positive) that is…
Matched conditions: ORAL CAVITY SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
Trial tests less invasive surgery to preserve neck function in oral cancer patients
Disease control Recruiting nowThis study is comparing two different surgical approaches for patients with early-stage oral cavity cancer that hasn't spread to the lymph nodes. It aims to see if a less invasive procedure, called a sentinel lymph node biopsy, is as effective as the standard, more extensive neck…
Matched conditions: ORAL CAVITY SQUAMOUS CELL CARCINOMA
Phase: PHASE2, PHASE3 • Sponsor: NRG Oncology • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC
-
New drug combo aims to supercharge immune system to fight cancer before surgery
Disease control Recruiting nowThis study is testing if adding a new immune-boosting drug (CDX-1140) to an existing immunotherapy (cemiplimab) works better before surgery for advanced head and neck cancer. The goal is to shrink the tumor more effectively, which could lead to less extensive surgery. About 44 pa…
Matched conditions: ORAL CAVITY SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:31 UTC
-
New weekly combo aims to control aggressive Head/Neck cancer
Disease control Recruiting nowThis study is testing a weekly combination of chemotherapy and immunotherapy for people with advanced head and neck cancer that has spread and who cannot take a standard chemotherapy drug called 5-FU. The goal is to see if this weekly schedule helps shrink tumors and control the …
Matched conditions: ORAL CAVITY SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Wake Forest University Health Sciences • Aim: Disease control
Last updated Mar 23, 2026 15:17 UTC
-
New drug aims to shield cancer patients from painful mouth sores
Symptom relief Recruiting nowThis study is testing if adding an investigational drug called BMX-001 to standard symptom care can better prevent severe mouth sores in people receiving combined chemotherapy and radiation for head and neck cancer. About 98 participants will be randomly assigned to receive eithe…
Matched conditions: ORAL CAVITY SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: NRG Oncology • Aim: Symptom relief
Last updated Mar 16, 2026 15:26 UTC
-
Scientists hunt blood clues to personalize cancer care
Knowledge-focused Recruiting nowThis study aims to find immune system markers in blood, saliva, and stool that can predict how well a different chemotherapy drug works for head and neck cancer patients who cannot take the standard drug. Researchers will analyze samples from 250 patients receiving chemoradiother…
Matched conditions: ORAL CAVITY SQUAMOUS CELL CARCINOMA
Sponsor: University of Erlangen-Nürnberg Medical School • Aim: Knowledge-focused
Last updated Apr 01, 2026 14:43 UTC